404

Not Found

Is this what you were looking for?

ib modules linktrack php
By Amy Swinderman

Forming a pharma fund

Index Ventures, GSK and J&J align to make $240 million in venture-capital funding available to life-science companies with early-stage assets
By Jeffrey Bouley

Making trials less of a trial

Janssen Research & Development announces establishment of databank to enhance global cross-pharmaceutical clinical trial efforts
By Jeffrey Bouley

Ariadne’s thread of connections

Bioinformatics company to collaborate in multimillion-dollar EU-based neuromuscular disease consortium to find biomarkers
By Lloyd Dunlap

Mayo yes, Myriad maybe

Supreme Court agrees with Mayo’s stance on Prometheus patent claims; sends Myriad Genetics case back to the Federal Circuit
By Arthur J. Hiller, SciFluor

Finding the right balance

If you’ve ever met with a financial planner or investment advisor, then you know that one of the first rules of investing is diversification, an important risk management technique that ensures there are a variety of assets within a portfolio. As biopharmaceutical organizations, it is important that we recognize the dire consequences that may result if we ignore this proven strategy.

Run a Search

March 2024 Issue Front Cover

Latest Issue  

• Volume 20 • Issue 2 • March 2024

March 2024

March 2024 Issue